SRPT - Sarepta Therapeutics - Stock & Dividends

Sarepta Therapeutics Inc. is a biopharmaceutical company that specializes in developing innovative treatments for rare diseases. At the forefront of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities, the company is committed to improving the lives of patients with debilitating conditions.

The company's portfolio of approved products includes EXONDYS 51, VYONDYS 53, and AMONDYS 45, all of which are designed to treat Duchenne muscular dystrophy (DMD), a severe genetic disorder that affects muscle degeneration. These treatments work by targeting specific genetic mutations, allowing for the production of a functional dystrophin protein, which is essential for muscle health. Additionally, Sarepta is developing ELEVIDYS, a gene therapy that uses an adeno-associated virus to deliver a healthy copy of the dystrophin gene to patients with DMD.

Sarepta's pipeline is robust, with several promising candidates in various stages of development. SRP-5051, a peptide-conjugated phosphorodiamidate morpholino oligomer (PMO), is being investigated as a potential treatment for DMD by targeting exon 51 of the dystrophin pre-mRNA. The company is also working on SRP-9003, a gene therapy program focused on treating limb-girdle muscular dystrophies, a group of genetic disorders that affect muscle strength and function.

Through strategic collaborations and license agreements with esteemed partners such as F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and Genevant Sciences, among others, Sarepta is accelerating the development of its innovative therapies. With a strong foundation in scientific research and a commitment to improving patient outcomes, the company is well-positioned to continue making a meaningful impact in the rare disease community.

Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts, and can be found online at https://www.sarepta.com.